Johnson & Johnson (JNJ)
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment.
Johnson & Johnson discontinues dengue drug study
Johnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.
2 Smart Income Stocks to Buy Right Now
These storied companies have a lot to offer different investors.
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
J&J to invest more than $2 billion in new manufacturing facility
Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
J&J subsidiary files for bankruptcy for third time to settle talc lawsuits
Under the proposal, Johnson & Johnson will pay $8B to claimants over 25 years.
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
